Abstract
Pfizer will pay $60 million for a stake in Homology Medicines, a Bedford, Massachusetts–based firm developing HMI-102, a gene therapy for adults with the metabolic disease phenylketonuria. Homology delivers genes with a suite of adeno-associated virus vectors derived from human hematopoietic stem cells that it says are taken up by the body more readily than traditional vectors.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
